Quick Answer
KYNTRA BIO, INC. reported Operating Income Loss of -$45.90 million for the year ending 2025.
- KYNTRA BIO, INC. showed an increase of +69.5% in Operating Income Loss from 2024 to 2025.
- This data is from KYNTRA BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), KYNTRA BIO, INC.'s Operating Income Loss has declined by 477.4%.
- Historical annual values: Fiscal year 2025: -$45.90 million | Fiscal year 2024: -$150.42 million | Fiscal year 2023: -$322.72 million | Fiscal year 2022: -$301.03 million | Fiscal year 2021: -$288.53 million | Fiscal year 2020: -$191.88 million | Fiscal year 2019: -$89.31 million | Fiscal year 2018: -$86.69 million | Fiscal year 2017: -$117.28 million | Fiscal year 2016: -$50.04 million | Fiscal year 2015: -$77.63 million | Fiscal year 2014: -$50.10 million | Fiscal year 2013: -$7.95 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: